Log in
NASDAQ:ATRS

Antares Pharma Stock Forecast, Price & News

$2.73
-0.07 (-2.50 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.70
Now: $2.73▼
$2.79
50-Day Range
$2.65
MA: $2.96▼
$3.37
52-Week Range
$1.60
Now: $2.73▼
$5.13
Volume1.12 million shs
Average Volume892,453 shs
Market Capitalization$453.43 million
P/E Ratio68.27
Dividend YieldN/A
Beta1.24
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Read More
Antares Pharma logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.84 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
Previous Symbol
CUSIP03664210
CIK1016169
Webwww.antarespharma.com
Phone609-359-3020
Employees178

Debt

Debt-to-Equity Ratio0.71
Current Ratio2.90
Quick Ratio2.41

Price-To-Earnings

Trailing P/E Ratio68.27
Forward P/E Ratio45.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$123.86 million
Price / Sales3.66
Cash Flow$0.00 per share
Price / Cash Flow859.25
Book Value$0.33 per share
Price / Book8.27

Profitability

EPS (Most Recent Fiscal Year)($0.01)
Net Income$-2,030,000.00
Net Margins4.04%
Return on Equity10.58%
Return on Assets4.15%

Miscellaneous

Outstanding Shares166,090,000
Market Cap$453.43 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$2.73
-0.07 (-2.50 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATRS shares have decreased by 9.0% and is now trading at $2.73.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Antares Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antares Pharma.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Antares Pharma.

How can I listen to Antares Pharma's earnings call?

Antares Pharma will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, topping the Zacks' consensus estimate of $0.00 by $0.01. The specialty pharmaceutical company earned $32.38 million during the quarter, compared to analyst estimates of $29.25 million. Antares Pharma had a return on equity of 10.58% and a net margin of 4.04%.
View Antares Pharma's earnings history.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $133.28 million.

What price target have analysts set for ATRS?

4 analysts have issued 1 year price objectives for Antares Pharma's shares. Their forecasts range from $4.50 to $7.00. On average, they anticipate Antares Pharma's share price to reach $5.63 in the next year. This suggests a possible upside of 106.0% from the stock's current price.
View analysts' price targets for Antares Pharma.

Are investors shorting Antares Pharma?

Antares Pharma saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 4,170,000 shares, a drop of 13.5% from the September 15th total of 4,820,000 shares. Based on an average daily volume of 911,700 shares, the days-to-cover ratio is currently 4.6 days. Approximately 2.7% of the company's stock are sold short.
View Antares Pharma's Short Interest.

Who are some of Antares Pharma's key competitors?

Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), Quidel (QDEL), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), OraSure Technologies (OSUR), Cerus (CERS), Meridian Bioscience (VIVO) and Anika Therapeutics (ANIK).
View all competitors.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 54, Pay $1.01M)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 59, Pay $590.73k)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 53, Pay $613.48k)
  • Mr. Patrick Madsen, Sr. VP of Operations
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 57)
  • Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
  • Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 72)
  • Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer
  • Mr. Greg Defilippis, Sr. VP of Device Bus. & Alliances
  • Dr. Steven Knapp M.S. Pharm.D., Sr. VP of Regulatory Affairs & Quality Assurance

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.32%), Perkins Capital Management Inc. (0.14%), Dupont Capital Management Corp (0.08%), Cornerstone Investment Partners LLC (0.03%), Diversified Trust Co (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma.

Which major investors are buying Antares Pharma stock?

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Assenagon Asset Management S.A., Cornerstone Investment Partners LLC, Diversified Trust Co, BNP Paribas Arbitrage SA, and LVW Advisors LLC.
View insider buying and selling activity for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.73.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $453.43 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 178 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.